PE20212261A1 - Extractos bacterianos estables como farmacos - Google Patents
Extractos bacterianos estables como farmacosInfo
- Publication number
- PE20212261A1 PE20212261A1 PE2021001517A PE2021001517A PE20212261A1 PE 20212261 A1 PE20212261 A1 PE 20212261A1 PE 2021001517 A PE2021001517 A PE 2021001517A PE 2021001517 A PE2021001517 A PE 2021001517A PE 20212261 A1 PE20212261 A1 PE 20212261A1
- Authority
- PE
- Peru
- Prior art keywords
- bacterial
- extract
- acid
- species
- culture medium
- Prior art date
Links
- 230000001580 bacterial effect Effects 0.000 title abstract 7
- 239000000284 extract Substances 0.000 title abstract 7
- 239000003814 drug Substances 0.000 title 1
- 229940079593 drug Drugs 0.000 title 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 abstract 3
- 241000894007 species Species 0.000 abstract 3
- ALRHLSYJTWAHJZ-UHFFFAOYSA-N 3-hydroxypropionic acid Chemical compound OCCC(O)=O ALRHLSYJTWAHJZ-UHFFFAOYSA-N 0.000 abstract 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 abstract 2
- 239000001963 growth medium Substances 0.000 abstract 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 abstract 2
- 150000007524 organic acids Chemical class 0.000 abstract 2
- 241000894006 Bacteria Species 0.000 abstract 1
- 239000002028 Biomass Substances 0.000 abstract 1
- 208000027244 Dysbiosis Diseases 0.000 abstract 1
- 241000606768 Haemophilus influenzae Species 0.000 abstract 1
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 241000588747 Klebsiella pneumoniae Species 0.000 abstract 1
- 241000588655 Moraxella catarrhalis Species 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 235000011054 acetic acid Nutrition 0.000 abstract 1
- 230000001154 acute effect Effects 0.000 abstract 1
- 150000001720 carbohydrates Chemical class 0.000 abstract 1
- 230000001684 chronic effect Effects 0.000 abstract 1
- 230000007140 dysbiosis Effects 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 229940047650 haemophilus influenzae Drugs 0.000 abstract 1
- 208000026278 immune system disease Diseases 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 239000004310 lactic acid Substances 0.000 abstract 1
- 235000014655 lactic acid Nutrition 0.000 abstract 1
- 239000007788 liquid Substances 0.000 abstract 1
- 230000002934 lysing effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 238000006386 neutralization reaction Methods 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 235000005985 organic acids Nutrition 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 235000019260 propionic acid Nutrition 0.000 abstract 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/742—Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/06—Lysis of microorganisms
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/08—Reducing the nucleic acid content
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P1/00—Preparation of compounds or compositions, not provided for in groups C12P3/00 - C12P39/00, by using microorganisms or enzymes
- C12P1/04—Preparation of compounds or compositions, not provided for in groups C12P3/00 - C12P39/00, by using microorganisms or enzymes by using bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55588—Adjuvants of undefined constitution
- A61K2039/55594—Adjuvants of undefined constitution from bacteria
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Otolaryngology (AREA)
- Pulmonology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Inorganic Chemistry (AREA)
- Dispersion Chemistry (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
La presente invencion se refiere a un extracto bacteriano de especies bacterianas Gram positivo y Gram negativo, en donde dichas especies bacterianas se seleccionan entre Moraxella catarrhalis, Haemophilus influenzae, Klebsiella pneumoniae, entre otras. Dicho extracto bacteriano puede ser obtenido mediante un proceso que comprende: a) cultivar cada especie de cepa bacteriana en un medio de cultivo adecuado; b) matar por calor a la bacteria, remover el medio de cultivo y recolectar la biomasa concentrada; c) lisar cada cepa en un pH inicial mayor de 10; d) disminuir el pH del(los) extracto(s) obtenido(s) en el paso (c), al agregar acidos organicos seleccionados entre acido acetico, acido propionico, acido lactico, acido 3-hidroxipropanoico, entre otros, una combinacion de los mismos, y/o sus esteres y sales farmaceuticamente aceptables; e) pasar el producto del paso (d) a traves de un microfiltro y retener el producto en un ultrafiltro para obtener un extracto soluble purificado; y (f) ajustar a un pH fisiologico final entre 5 y 8, al agregar acido organico o combinacion de lo mismo, usado para dicha neutralizacion. El extracto soluble purificado comprende 100 microgramos/ml de acidos nucleicos y 0.1 mg/ml de sacaridos, siendo estable en forma liquida a temperatura ambiente, 4°C, -20°C y -80°C. Tambien se refiere a formulaciones farmaceuticas basadas en los extractos bacterianos estabilizados y dispositivos de liberacion para el tratamiento y/o prevencion de trastornos inmunologicos agudos y cronicos resultantes de infecciones, inflamacion, neoplasmas y/o disbiosis.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP19162912 | 2019-03-14 | ||
PCT/EP2020/056742 WO2020182970A1 (en) | 2019-03-14 | 2020-03-12 | Process for making stable bacterial extracts and their use as pharmaceuticals |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20212261A1 true PE20212261A1 (es) | 2021-11-29 |
Family
ID=65991511
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2021001517A PE20212261A1 (es) | 2019-03-14 | 2020-03-12 | Extractos bacterianos estables como farmacos |
Country Status (19)
Country | Link |
---|---|
US (2) | US11801271B2 (es) |
EP (2) | EP3937957A1 (es) |
JP (1) | JP2022525177A (es) |
KR (1) | KR20210141546A (es) |
CN (1) | CN113840615A (es) |
AU (1) | AU2020235261A1 (es) |
BR (1) | BR112021018006A2 (es) |
CA (1) | CA3132564A1 (es) |
CL (1) | CL2021002401A1 (es) |
CO (1) | CO2021013677A2 (es) |
CR (1) | CR20210515A (es) |
CU (1) | CU20210077A7 (es) |
IL (1) | IL286215A (es) |
MA (1) | MA55291A (es) |
MX (1) | MX2021010912A (es) |
PE (1) | PE20212261A1 (es) |
SG (1) | SG11202109937UA (es) |
WO (1) | WO2020182970A1 (es) |
ZA (1) | ZA202106914B (es) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113613665A (zh) * | 2019-03-14 | 2021-11-05 | Om药物公司 | 治疗和/或预防哮喘、哮喘恶化、过敏性哮喘和/或与呼吸系统病症相关的微生物群相关的病症的方法 |
TW202304485A (zh) * | 2021-04-12 | 2023-02-01 | 香港中文大學 | 用於增強免疫力的方法和組合物 |
WO2022233441A1 (en) * | 2021-05-07 | 2022-11-10 | Symrise Ag | Novel bacterial ferment of lactobacillus species |
EP4134426A1 (en) * | 2021-08-13 | 2023-02-15 | Symrise AG | Novel bacterial ferment of lactobacillus species |
WO2023120547A1 (ja) * | 2021-12-22 | 2023-06-29 | 株式会社明治 | 二次性感染症の予防又は発症リスクを低減するための組成物 |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR8007911A (pt) | 1979-12-06 | 1981-06-16 | Glaxo Group Ltd | Inalador aperfeicoado |
DE3274065D1 (de) | 1981-07-08 | 1986-12-11 | Draco Ab | Powder inhalator |
US4811731A (en) | 1985-07-30 | 1989-03-14 | Glaxo Group Limited | Devices for administering medicaments to patients |
SK280967B6 (sk) | 1990-03-02 | 2000-10-09 | Glaxo Group Limited | Inhalačný prístroj |
CH685498A5 (fr) | 1992-02-14 | 1995-07-31 | Om Lab Sa | Extrait de macromolécules bactériennes, procédé pour sa préparation et composition pharmaceutique contenant cet extrait. |
US5497763A (en) | 1993-05-21 | 1996-03-12 | Aradigm Corporation | Disposable package for intrapulmonary delivery of aerosolized formulations |
DE19536902A1 (de) | 1995-10-04 | 1997-04-10 | Boehringer Ingelheim Int | Vorrichtung zur Hochdruckerzeugung in einem Fluid in Miniaturausführung |
US7171965B2 (en) | 2000-02-01 | 2007-02-06 | Valois S.A.S. | Breath actuated dry powder inhaler and tape dose strip |
US6994083B2 (en) | 2001-12-21 | 2006-02-07 | Trudell Medical International | Nebulizer apparatus and method |
WO2006060282A2 (en) * | 2004-11-30 | 2006-06-08 | Merial Limited | Mixing devices for chemical lysis of cells |
US20080170996A1 (en) * | 2006-07-28 | 2008-07-17 | The Board Of Regents Of The University Of Texas System | Compositions and Methods for Stimulation of Lung Innate Immunity |
DK2114421T3 (en) | 2007-03-05 | 2018-04-23 | Om Pharma | BACTERIA EXTRACTS FOR RESPIRATORY DISORDERS AND PROCEDURES FOR PREPARING THEREOF |
JP6041458B2 (ja) | 2007-03-05 | 2016-12-07 | オーエム ファーマOm Pharma | 消化管又は尿管の障害のための細菌抽出物及びその製造方法 |
GB0818453D0 (en) * | 2008-10-08 | 2008-11-12 | Novartis Ag | Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom |
ES2356883B1 (es) | 2008-07-24 | 2012-02-22 | Bcn Peptides, S.A. | Composición para el tratamiento del dolor y/o la inflamación. |
RU2500412C2 (ru) | 2008-09-04 | 2013-12-10 | Ом Фарма | ИММУНОМОДУЛИРУЮЩИЕ ЭКСТРАКТЫ ИЗ БАКТЕРИЙ Lactobacillus И СПОСОБЫ ИХ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЯ |
RU2425691C1 (ru) | 2010-07-15 | 2011-08-10 | ВАКЕ спол с.р.о. | Аэрозольный препарат на основе апротинина для лечения вирусных респираторных инфекций |
CN101979541A (zh) * | 2010-10-28 | 2011-02-23 | 徐堤 | 一种快速共价闭合环状dna纯化试剂盒 |
CN110290799A (zh) * | 2016-12-13 | 2019-09-27 | 防御素治疗学公司 | 用于治疗肺部炎性病症的方法 |
-
2020
- 2020-03-12 CU CU2021000077A patent/CU20210077A7/es unknown
- 2020-03-12 MA MA055291A patent/MA55291A/fr unknown
- 2020-03-12 KR KR1020217032875A patent/KR20210141546A/ko unknown
- 2020-03-12 EP EP20712877.8A patent/EP3937957A1/en active Pending
- 2020-03-12 WO PCT/EP2020/056742 patent/WO2020182970A1/en active Application Filing
- 2020-03-12 CR CR20210515A patent/CR20210515A/es unknown
- 2020-03-12 BR BR112021018006A patent/BR112021018006A2/pt unknown
- 2020-03-12 JP JP2021555329A patent/JP2022525177A/ja active Pending
- 2020-03-12 CN CN202080035416.0A patent/CN113840615A/zh active Pending
- 2020-03-12 SG SG11202109937U patent/SG11202109937UA/en unknown
- 2020-03-12 MX MX2021010912A patent/MX2021010912A/es unknown
- 2020-03-12 EP EP23181587.9A patent/EP4234026A3/en active Pending
- 2020-03-12 AU AU2020235261A patent/AU2020235261A1/en active Pending
- 2020-03-12 PE PE2021001517A patent/PE20212261A1/es unknown
- 2020-03-12 CA CA3132564A patent/CA3132564A1/en active Pending
-
2021
- 2021-09-09 IL IL286215A patent/IL286215A/en unknown
- 2021-09-14 CL CL2021002401A patent/CL2021002401A1/es unknown
- 2021-09-14 US US17/474,242 patent/US11801271B2/en active Active
- 2021-09-17 ZA ZA2021/06914A patent/ZA202106914B/en unknown
- 2021-10-13 CO CONC2021/0013677A patent/CO2021013677A2/es unknown
-
2023
- 2023-06-30 US US18/345,619 patent/US20230346855A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
US20230346855A1 (en) | 2023-11-02 |
CL2021002401A1 (es) | 2022-04-08 |
US20210401902A1 (en) | 2021-12-30 |
CR20210515A (es) | 2022-03-28 |
KR20210141546A (ko) | 2021-11-23 |
MX2021010912A (es) | 2021-10-01 |
CO2021013677A2 (es) | 2021-10-20 |
EP3937957A1 (en) | 2022-01-19 |
SG11202109937UA (en) | 2021-10-28 |
CA3132564A1 (en) | 2020-09-17 |
CN113840615A (zh) | 2021-12-24 |
CU20210077A7 (es) | 2022-04-07 |
WO2020182970A1 (en) | 2020-09-17 |
ZA202106914B (en) | 2023-10-25 |
BR112021018006A2 (pt) | 2021-11-16 |
EP4234026A2 (en) | 2023-08-30 |
IL286215A (en) | 2021-10-31 |
US11801271B2 (en) | 2023-10-31 |
MA55291A (fr) | 2022-01-19 |
JP2022525177A (ja) | 2022-05-11 |
AU2020235261A1 (en) | 2021-09-16 |
EP4234026A3 (en) | 2024-07-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20212261A1 (es) | Extractos bacterianos estables como farmacos | |
Jia et al. | Nasal and pulmonary vaccine delivery using particulate carriers | |
KR102503163B1 (ko) | 엔테로코커스 패칼리스를 유효성분으로 함유하는 염증성 질환 예방 또는 치료용 조성물 | |
EP1615657A1 (fr) | Produit immunomodulateur obtenu a partir d'une culture de bifidobacterium et compositions le contenant | |
KR102084973B1 (ko) | 엔테로코커스 패칼리스를 유효성분으로 포함하는 대장염 예방 또는 치료용 조성물 | |
KR102337993B1 (ko) | 클로스트리디움 렙텀 균주, 및 그의 유래의 소포체 및 그의 항염증 및 항균 용도 | |
Srikanth et al. | Chocolate mouth rinse: Effect on plaque accumulation and mutans streptococci counts when used by children | |
JP2021167338A (ja) | 口腔内微生物群の成長促進用組成物及びその使用方法 | |
TW202022109A (zh) | 新穎乳酸菌株及包含新穎乳酸菌株之免疫賦活劑 | |
KR102337991B1 (ko) | 코프로코커스 유탁터스 균주, 및 그의 유래의 소포체 및 그의 항염증 및 항균 용도 | |
Giri et al. | Is intranasal vaccination a feasible solution for tuberculosis? | |
Russell et al. | Mucosal vaccines: an overview | |
CN101978864A (zh) | 一种油菜蜂花粉提取物及其应用 | |
CN114007440B (zh) | 组合物用于预防、治疗或改善胃肠道疾病的用途 | |
JP2010526125A (ja) | ハイビスカスの新規使用、特に製薬的使用 | |
JP2008063241A (ja) | 免疫賦活剤 | |
JP5945317B2 (ja) | インフルエンザウイルス感染抑制剤 | |
KR20220079092A (ko) | 신규 균주를 포함하는 염증성 질환 예방 또는 치료용 조성물 | |
Han et al. | Non-invasive vaccines: challenges in formulation and vaccine adjuvants | |
JP6928225B2 (ja) | 経口ワクチン製剤、並びに感染症予防方法 | |
JP7393805B2 (ja) | 抗菌性組成物及びその製造方法 | |
JP2018111658A (ja) | ノロウイルス排出促進用組成物及びノロウイルス二次感染防止用組成物 | |
Springer et al. | Protection of mice against lethal Staphylococcus infection by Escherichia coli O86 fractions | |
WO2017090769A1 (ja) | インフルエンザワクチン乾燥製剤、及び、インフルエンザワクチン乾燥製剤の製造方法 | |
US20020032152A1 (en) | Anti-helicobacter vaccine complex |